Spyre Therapeutics (SYRE) Gains from Sales and Divestitures (2015 - 2018)
Spyre Therapeutics posted quarterly Gains from Sales and Divestitures of $21645.0 for Q4 2018, down 33.58% on a QoQ basis from $32588.0 in Q4 2015.
Spyre Therapeutics (SYRE) has 2 years of Gains from Sales and Divestitures data on file, last reported at $21645.0 in Q4 2018.
- For the quarter ending Q4 2018, Gains from Sales and Divestitures changed N/A year-over-year to $21645.0; the trailing twelve-month figure through Dec 2018 stood at $21645.0 (changed N/A YoY), and the FY2018 full-year result was $21645.0, changed N/A from the prior year.
- Gains from Sales and Divestitures for Q4 2018 stood at $21645.0, down from $32588.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $32588.0 in Q4 2015 and bottomed at $21645.0 in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 21,645.00 |
| Dec 31, 2018 | 21,645.00 |
| Dec 31, 2015 | 32,588.00 |
| Dec 31, 2015 | 32,588.00 |